G1 Therapeutics, Inc.

Good day and thank you for standing by. Welcome to the G1 Therapeutics First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require assistance during the conference, please press star 0. I would now like to hand the conference over to Will Roberts, Head of Communications. Please go ahead.

Thank you, Abigail. Good morning, everyone, and welcome to the G1 conference call to discuss our first quarter of 2022 financial results and business update. The press release on these financial results was issued this morning and can be found in the news section of our corporate website, g1therapeutics.com. On this morning's call, the team will provide a business overview of the first quarter of 2022, including an update on our clinical programs and our commercial progress in that period with Casella, which is approved and commercially available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum etoposide-containing regimen or a topotecan-containing regimen for extensive-stage small cell lung cancer, or ES-SCLC. A question and answer session will follow the prepared remarks. Before we begin, I'd like to remind you that today's webcast contains forward-looking statements within the meaning of the Private Security Litigation Reform Act of 1995. Such statements represent management's judgment as of today and may involve risk and uncertainties that could cause actual results to differ materially from those expressed in or implied by these statements. For more information on such risk and uncertainties, Please refer to our filings with the Securities and Exchange Commission, which are available from the SEC or on our corporate website. Any forward-looking statements represent our views as of today, May 4th, 2022. Joining me on the call today are Jack Bailey, our Chief Executive Officer, Andrew Perry, our Chief Commercial Officer, Raj Malek, our Chief Medical Officer, and Jack Moses, our Chief Financial Officer. I'll now turn the call over to Jack. Jack? Thanks, Will.

Good morning, everyone, and thank you for joining us on the call today. Today's headline is that as of the beginning of March, we have successfully deployed our G1 sales team, fully transitioned out of our sales relationship with Behringer Ingelheim, and in doing so have entered a new phase of COSELLA promotion in which we are in full control of the commercial opportunity for this important drug. COSELLA is a unique and innovative drug. that can fundamentally change the paradigm by which small cell lung cancers are treated. It's proactively administered and covers multiple lineages, unlike what practitioners have been doing for the last 30 years, namely treating hematologic events caused by chemo reactively with a variety of single lineage interventions which carry their own unintended consequences. Our goal over time is to replace these reactive treatment modalities with COSELLA, a simple 30-minute infusion prior to chemo to reduce and in some cases eliminate the cytotoxic events that put chemo patients in the hospital and prevent them from completing their regimens. We are excited about this, as are the people we hear routinely from, including patients who have been through chemotherapy with COSELLA, infusion center nurses on the front line of patient care, and treating oncologists. As you will hear from Andrew, our newly deployed sales team made good progress during the back half of the first quarter in improving Cosella access and uptake. Intent to use remains high, and reimbursement remains as strong as it has been since launch. Importantly, ordering by our top 100 organizations increased quarter over quarter, and more broadly, we continued to shift the proportion of our business toward those top 100 organizations. So not only did overall volume increase, it increased in the accounts that have the ability to maximize the future potential of CoSella. Turning to our clinical operations, we continue to make good progress in enrollment in our ongoing Phase II and Phase III trials. And as of today, we are on plan to provide initial results on schedule. This morning, I will ask Andrew to cover our recent commercial progress, including an update on the first quarter of 2022 and month-over-month progress during the quarter, the first opportunity in which we were in full control of the commercialization effort. Raj will then provide an update on some of our medical and clinical momentum, including the real-world data we recently presented at the 2022 NCCN meeting. Finally, Jen will provide the financial results for the quarter, including a reminder that our cash runway takes us into 2024. Then I'll be back for some concluding comments. With that, I will turn the call over to Andrew.